VUG

(redirected from vesicoureteral reflux)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia, Wikipedia.
AcronymDefinition
VUGVaio User'S Group
VUGVirtual User Group
VUGVision User Group
VUGVista User Group
VUGVoip User Group
VUGVivendi Universal Games
VUGVirtual University Gazette (online resource)
VUGVirtual User Group (online meeting forum)
VUGVisualization and Usability Group
VUGVesicoureteral Reflux (medical)
VUGVehicle User Group (UK)
References in periodicals archive ?
(20) reported results of biofeedback treatment in children aged 5-14 years with DV and vesicoureteral reflux.They reported significant, improvements in enuresis, daytime wetting, constipation, frequency and urgency (82%, 70%, 78%, 76% and 71%, respectively) in older children who received biofeedback therapy.
Acoustic radiation force impulse (ARFI) in the evaluation of the renal parenchymal stiffness in paediatric patients with vesicoureteral reflux: preliminary results.
Vesicoureteral reflux and clinical outcomes in infants with prenatally detected hydronephrosis.
In this study, the efficacy of Gil-Vernet antireflux technique in primary high-grade vesicoureteral reflux is assessed.
Surgical management via diverticulectomy is warranted whenever the patient suffers from recurrent UTIs, bladder stones, complicated vesicoureteral reflux, voiding dysfunction, and urinary retention [8].
Since FDA approval in 2001, DxHA (Deflux) has been commonly used in the pediatric population to treat vesicoureteral reflux [10].
The right ureter was very dilated, with a maximum diameter of more than 3 cm, as shown in Figure 5, because of grade 4 vesicoureteral reflux.
The diagnosis criteria were: 1) renal insufficiency in diagnosis; 2) results of imaging examinations on urinary tract showed that renal pelvis and/or ureter were full-filled or dilated; and 3) results of imaging examinations on urinary tract showed vesicoureteral reflux (VUR).
Ipsilateral ureteroureterostomy for the treatment of vesicoureteral reflux or obstruction associated with complete ureteral duplication.
Exclusion criteria included symptomatic patients (such as UTI or pain), bilateral UPJO, presence of urinary tract stone, presence of vesicoureteral reflux (VUR), chronic renal failure (CRF), malignancy, abnormal liver function, and abnormal level of creatinine and blood urea nitrogen and also patients with fever or any viral infections.
BULKAMID is an effective treatment for stress urinary incontinence (SUI) and vesicoureteral reflux (VUR).
Late complications involved a de novo diagnosis of vesicoureteral reflux and ureteral strictures.